{"organizations": [], "uuid": "6803839f97d2c05f09e06a1c4830748d0f057bef", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180420.html", "section_title": "Archive News &amp; Video for Friday, 20 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biogen-and-ionis-expand-strategic/brief-biogen-and-ionis-expand-strategic-collaboration-to-develop-drug-candidates-for-a-broad-range-of-neurological-diseases-idUSFWN1RM0DU", "country": "US", "domain_rank": 408, "title": "BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.188, "site_type": "news", "published": "2018-04-20T22:33:00.000+03:00", "replies_count": 0, "uuid": "6803839f97d2c05f09e06a1c4830748d0f057bef"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biogen-and-ionis-expand-strategic/brief-biogen-and-ionis-expand-strategic-collaboration-to-develop-drug-candidates-for-a-broad-range-of-neurological-diseases-idUSFWN1RM0DU", "ord_in_thread": 0, "title": "BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "biogen inc", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "broad range of neurological diseases", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 20 (Reuters) - Biogen Inc:\n* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES\n* BIOGEN INC - BIOGEN WILL PAY IONIS $1 BILLION IN CASH, INCLUDING AN EQUITY INVESTMENT IN IONIS STOCK AND AN UPFRONT PAYMENT\n* BIOGEN INC - WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF COLLABORATION AND WILL BE RESPONSIBLE FOR THEIR DEVELOPMENT AND COMMERCIALIZATION\n* BIOGEN INC - $1 BILLION PAYMENT INCLUDES $625 MILLION TO BUY 11.5 MILLION SHARES OF IONIS COMMON STOCK AT $54.34 PER SHARE, $375 MILLION UPFRONT PAYMENT\n* BIOGEN INC - UNDER TERMS OF COLLABORATION CO MAY PAY MILESTONE PAYMENTS, LICENSE FEES AND ROYALTIES ON NET SALES\n* BIOGEN INC - IN COLLABORATION, IONIS WILL BE RESPONSIBLE FOR IDENTIFICATION OF ANTISENSE DRUG CANDIDATES BASED ON SELECTED TARGETS\n* BIOGEN - IN COLLABORATION BIOGEN WILL BE RESPONSIBLE FOR AND PAY FOR NON-CLINICAL STUDIES, CLINICAL DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION\n* BIOGEN - CO, IONIS EXPANDED COLLABORATION THROUGH NEW 10-YEAR AGREEMENT TO DEVELOP NOVEL ANTISENSE DRUG CANDIDATES FOR RANGE OF NEUROLOGICAL DISEASES Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-20T22:33:00.000+03:00", "crawled": "2018-04-21T18:07:25.003+03:00", "highlightTitle": ""}